MOONLAKE IMMUNOTHERAPEUTICS Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax of $11.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax · last filed 2026-02-25
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2024-12-31 was $17.64K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2024-09-30 was -$2.58K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2024-06-30 was -$2.48K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for the quarter ending 2024-03-31 was -$2.57K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for fiscal 2025 was $11.00K, a 10.00% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for fiscal 2024 was $10.00K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for fiscal 2023 was -$107.00K.
- MOONLAKE IMMUNOTHERAPEUTICS other comprehensive (income) loss, defined benefit plan, prior service cost (credit), before tax for fiscal 2022 was $0.00.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 12 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $11.00K 10-K · filed 2026-02-25 | ||||
| 2024-12-31 | $17.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.06K derived: sum of 2 quarters · filed 2026-02-25 | $12.58K derived: sum of 3 quarters · filed 2026-02-25 | $10.00K 10-K · filed 2026-02-25 | $10.18K 10-K · filed 2025-02-26 |
| 2024-09-30 | -$2.58K 10-Q · filed 2024-11-07 | -$5.06K derived: sum of 2 quarters · filed 2024-11-07 | -$7.64K 10-Q · filed 2024-11-07 | -$114.63K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | -$2.48K 10-Q · filed 2024-08-07 | -$5.06K 10-Q · filed 2024-08-07 | -$112.05K derived: sum of 3 quarters · filed 2026-02-25 | -$112.05K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | -$2.57K 10-Q · filed 2024-05-07 | -$109.57K derived: sum of 2 quarters · filed 2026-02-25 | -$109.57K derived: sum of 3 quarters · filed 2026-02-25 | -$109.57K derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | -$107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$107.00K derived: sum of 2 quarters · filed 2026-02-25 | -$107.00K derived: sum of 3 quarters · filed 2026-02-25 | -$107.00K 10-K · filed 2026-02-25 | -$107.75K 10-K · filed 2024-02-29 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |